Although mutation of NF1 has been described in non-small cell lung cancer (NSCLC), co-mutation with RASA1, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. RASA1/NF1 mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients.
from Cancer via ola Kala on Inoreader http://ift.tt/2Dkoe4K
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου